# Be Biopharma

> Be Biopharma (Be Bio) is a Cambridge, Massachusetts biotechnology company pioneering a new class of therapies called Engineered B Cell Medicines (BCMs). By precisely gene-editing a patient's own B cells - nature's protein factories that can secrete high volumes of protein for decades - Be Bio aims to deliver durable, potentially re-dosable treatments for hemophilia, rare genetic diseases, and other serious conditions. Founded in 2020 out of Seattle Children's Research Institute and Longwood Fund, the company has raised roughly $356 million and, as of early 2025, advanced to a multi-program clinical-stage company led by CEO Joanne Smith-Farrell, Ph.D.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** David Rawlings (Scientific Co-Founder (Seattle Children's Research Institute)), Richard James (Scientific Co-Founder (Seattle Children's Research Institute)), Longwood Fund (Founding Investor / Company Builder)
- **Team size:** Approximately 46-52 employees (2025-2026)
- **Products:** Engineered B Cell Medicines (BCM) Platform, BE-101, BE-102
- **Notable:** Pioneered and named an entirely new therapeutic modality - Engineered B Cell Medicines (BCMs)., Advanced BE-101 to first-in-human dosing in the BeCoMe-9 Phase 1/2 hemophilia B trial., Received FDA Fast Track designation and IND clearance for BE-101.

## Products & services

- **Engineered B Cell Medicines (BCM) Platform** — A proprietary platform that uses precision genome editing to reprogram primary human B cells into terminally-differentiated plasma cells that secrete high levels of therapeutic protein, engraft without preconditioning, persist for years, and can potentially be re-dosed.
- **BE-101** — Lead engineered B cell medicine that inserts the human Factor IX (FIX) gene into B cells to continuously produce clotting factor for people with moderately severe to severe hemophilia B. Received FDA Fast Track designation; evaluated in the Phase 1/2 BeCoMe-9 trial (NCT06611436), which was later discontinued as a strategic business decision (not for safety).
- **BE-102** — Engineered B cell medicine designed to produce alkaline phosphatase for hypophosphatasia, a rare metabolic bone disorder. Named a development candidate with planned clinical entry.

## Achievements

- Pioneered and named an entirely new therapeutic modality - Engineered B Cell Medicines (BCMs).
- Advanced BE-101 to first-in-human dosing in the BeCoMe-9 Phase 1/2 hemophilia B trial.
- Received FDA Fast Track designation and IND clearance for BE-101.
- Raised roughly $356M in total funding across Series A-C from top-tier life science investors.
- Transitioned from a single-program to a multi-program, clinical-stage company (BE-101 and BE-102).
- Spun proprietary B cell engineering technology out of Seattle Children's Research Institute into a venture-backed company.

## Latest updates

- **2026-06** — Be Bio ended its Phase 1/2 BeCoMe-9 study of lead program BE-101 as a strategic business decision - not linked to any safety concern - after enrolling five of an anticipated 24 patients.
- **2025-01** — Closed a $92M Series C financing and announced its transition to a multi-program, clinical-stage company; Nextech Invest joined the syndicate and Melissa McCracken joined the board.
- **2024-12** — Announced first participant dosed in the BeCoMe-9 trial of BE-101 in hemophilia B.
- **2024-10** — Raised $82M in additional financing to advance the pipeline.
- **2024-09** — BE-101 received FDA Fast Track designation for hemophilia B.

## Links

- Website: https://be.bio
- LinkedIn: http://www.linkedin.com/company/be-biopharma-inc
- Twitter/X: https://twitter.com/bebiopharma

---

Profile page: https://yespress.io/be-biopharma
Published by YesPress — https://yespress.io
Last updated: 2026-07-22